Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. - Wikidata - wikimedia - TriplyDB

Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.

Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.

http://www.wikidata.org/entity/Q34682223

about

Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy Antiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis.Targeted therapies for adrenocortical carcinoma: IGF and beyond.Radioimmunotherapy with α-particle-emitting radionuclides.Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia Inhibition of Lysyl Oxidases Improves Drug Diffusion and Increases Efficacy of Cytotoxic Treatment in 3D Tumor Models Distribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer.Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation.Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma.Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles.Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer.VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.Actinium-225 in targeted alpha-particle therapeutic applications.Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma.Combination of intra-arterial therapies and sorafenib: is there a clinical benefit?In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours.Tumor vascular microenvironment determines responsiveness to photodynamic therapy.Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics.Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.Structure and properties of DOTA-chelated radiopharmaceuticals within the Ac decay pathway

P2860

Q26828930-108117CE-6E77-4BC2-8649-6C94451FCE75 Q30540674-4E36C34D-A7DB-4BBD-9654-4CC967F4CB13 Q33765417-13B76C91-9D70-4F54-9140-CC06C7A05321 Q33912305-F4E2874E-4549-4489-B4C5-0283431558B9 Q34101433-D6B84B21-53C8-4543-B568-E04D1B6827BD Q34419562-DE75F8B2-5108-4CA3-837D-EFC4C0640C62 Q35078406-BF3678A9-AA25-417E-A6DB-D09798AC49E7 Q35523959-149E8FA0-4A66-4972-A95C-EC06AEAE9F85 Q35552373-6D64AFB7-FB89-4710-9CD0-D40F6B76F0DC Q35751307-5CBBA5F4-5F21-489C-84D2-85BD8EBC62C7 Q36100135-C52E4490-3FC5-4991-AB28-ED257D38FBE4 Q36334121-4309555A-D071-4BAD-AD2E-4AE8EDBF1157 Q36417444-787EB297-748C-4214-B645-4FF528D2C022 Q36447756-382AC51D-F0C0-4AD1-BD1A-9283C4B4912A Q36653033-FB40D08C-E178-456A-9FBB-22DA68B42325 Q36676175-E24C601E-5371-4441-AF07-834530AAF1F1 Q36782265-C02AA2E4-8AA1-4414-818A-6F07ADE3BEBC Q37309920-1B26B99A-191D-469D-A98C-DED543829BE9 Q37389371-AD673AAF-44CF-431D-A4EE-E4C18DCABEFA Q37517611-1B723366-FE46-4AC1-BCC8-B9FD0DE78F5E Q37587264-5369D5F5-8018-4E2E-AEB8-EE3E89551542 Q37971807-8B404EF8-56DA-4677-A1E8-5D966711409C Q38150356-21587D90-A35A-45AC-9CE9-C7C350304C02 Q38155510-98F178BE-6DCD-439C-83E3-B355B04735E5 Q38217457-0DBBD3C7-176D-4B75-8AF2-ABA726AA4F9F Q39257411-952647A0-9182-4FAC-B5BF-8E09F2FA351D Q39388400-F2F4EE1F-1624-42DD-9030-8F1120EE15F7 Q39413582-60AD401E-6531-44D4-9D11-252AAAAB4262 Q41099763-F79A2B3A-C8F6-415B-8DDB-F4CF9DDE471A Q42483948-DECFFF0F-951E-42FD-A935-9A4E9F8F9F66 Q57179186-EE630AE3-BF32-4D21-ADDE-5F0F1336077B

P2860

Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.

http://www.wikidata.org/entity/Q34682223

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Selective killing of tumor neo ...... emotherapy delivery to tumors.

@ast

Selective killing of tumor neo ...... emotherapy delivery to tumors.

@en

Selective killing of tumor neo ...... emotherapy delivery to tumors.

@nl

type

label

Selective killing of tumor neo ...... emotherapy delivery to tumors.

@ast

Selective killing of tumor neo ...... emotherapy delivery to tumors.

@en

Selective killing of tumor neo ...... emotherapy delivery to tumors.

@nl

prefLabel

Selective killing of tumor neo ...... emotherapy delivery to tumors.

@ast

Selective killing of tumor neo ...... emotherapy delivery to tumors.

@en

Selective killing of tumor neo ...... emotherapy delivery to tumors.

@nl

P1433

Q34682223-B17BF76F-7099-4E70-9893-B028BD314BE4

P1476

Q34682223-96AA8913-7473-479B-B4C2-735D268A3B5F

P2093

Q34682223-1839513D-E217-4957-B2FD-DC02D420126B

Q34682223-56D17C37-5216-4BE7-B660-9E56BC88F91F

Q34682223-7A1396FA-5C0B-49C7-B209-3C133613D3C9

Q34682223-970FA0D0-D994-4E4A-A440-3301C4E05E96

Q34682223-985C5261-7CDB-4D8A-965C-1AF212DE9015

Q34682223-A47F64D7-4BC8-44F9-BCC1-E862208AA85D

Q34682223-AC09B264-E235-4451-BD88-B4B360603F33

Q34682223-CD341CA9-34B5-4222-AD11-15DEE83CD4EF

P2860

Q34682223-04F990E2-BE95-459F-BE83-777B6DC513A7

Q34682223-0638E579-678B-4617-B0CF-A65AC9306565

Q34682223-1C79AB5D-684E-4063-87E9-4BBC835E8D49

Q34682223-2830D3D7-9935-466A-AE31-DBF2B4F23649

Q34682223-2D58196D-AC51-4962-82DA-E7CFAB6B5D4F

Q34682223-2F388BE6-499E-4EC6-998E-4B660D85A73F

Q34682223-530F91C1-521D-4FD2-9514-0E1D96A68DD3

Q34682223-54F86479-822A-4641-8AF3-AF88ABDEADEB

Q34682223-6612B2FE-4427-4A61-A610-00A161D650A1

Q34682223-70267E0A-0A41-41CE-B393-D47A2E9FD36D

P304

Q34682223-F16D4294-AD8C-438E-83A3-4F665248DA51

P31

Q34682223-AE3DEFC6-4C57-46A6-A930-057B6470DBC2

P356

Q34682223-7D31F0CC-F5E1-416F-9F72-55F148773A9A

P407

Q34682223-F7257F05-D144-444D-B0D2-544D1A17D829

P433

Q34682223-B4DE5A5F-167D-44CC-AEA4-7CCDD07B751A

P478

Q34682223-F613D2D8-866E-46AB-A898-62F0A9963C8E

P577

Q34682223-8F0D1746-1FB9-4E08-81C7-D6BF00F2367A

P698

Q34682223-DC9C0DC2-19AC-42ED-9705-31036410FE29

P921

Q34682223-57349168-F7A5-4E4A-8111-80EBE1C97F60

P932

Q34682223-D09F3420-B3B8-43D2-942F-A136FDACF4FF

P356

0008-5472.CAN-10-2029

P1433

Cancer Research

P1476

Selective killing of tumor neo ...... emotherapy delivery to tumors.

@en

P2093

Carlos H Villa

http://www.w3.org/2001/XMLSchema#string

David A Scheinberg

http://www.w3.org/2001/XMLSchema#string

Erik Henke

http://www.w3.org/2001/XMLSchema#string

Freddy E Escorcia

http://www.w3.org/2001/XMLSchema#string

Michael R McDevitt

http://www.w3.org/2001/XMLSchema#string

Peter Smith-Jones

http://www.w3.org/2001/XMLSchema#string

Robert Benezra

http://www.w3.org/2001/XMLSchema#string

Ronald G Blasberg

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization

Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Tumor angiogenesis

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.

Interaction between bevacizumab and murine VEGF-A: a reassessment.

Mechanisms for the biological effectiveness of high-LET radiations.

P304

9277-9286

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-2029

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21045141

http://www.w3.org/2001/XMLSchema#string

P921

P932

3058681

http://www.w3.org/2001/XMLSchema#string